ABIOMED, INC.

Abiomed is a leading manufacturer of percutaneous mechanical circulatory support systems, headquartered in Danvers, Massachusetts. The company specializes in the Impella family of heart pumps—catheter-based, minimally invasive devices designed to provide hemodynamic support and left ventricular unloading in acute heart failure, cardiogenic shock, and high-risk percutaneous coronary intervention (PCI) settings. Impella represents the world's smallest heart pump technology and is used to facilitate myocardial recovery and protect native heart function during complex cardiac procedures. The company's product portfolio includes multiple Impella configurations targeting different clinical scenarios, from acute myocardial infarction and cardiogenic shock to elective protected PCI in patients with severe coronary artery disease or advanced heart failure. Abiomed provides comprehensive clinical support services including on-site, on-call, and online technical and clinical assistance to healthcare professionals. The company maintains a global footprint with major operational centers in the United States (Danvers, Woburn, Baltimore), Europe (Aachen, Berlin), and Japan. Abiomed is a Johnson & Johnson MedTech company and operates within the cardiac support and interventional cardiology market. Clinical evidence demonstrates long-term survival benefits and myocardial recovery outcomes associated with Impella-supported procedures, supported by randomized controlled trials and registry data presented at major cardiology conferences.